Company intelligence / Profile preview
TreeFrog Therapeutics
Pessac/Bordeaux, Nouvelle-Aquitaine, Francetreefrog.fr ↗
- Ownership
- Private
- Employees
- ~130
- Development stage
- Preclinical
01
Overview
Successfully demonstrated bioproduction of a Parkinson's Disease cell therapy in a scalable bioreactor, leading to full behavioral recovery 16 weeks after transplantation using a cryopreserved 3D microtissue format. Published results in Neurotherapeutics journal in 2024[6].
- Therapeutic areas
- OncologyNeurology
- Modalities
- Cell therapyiPSC-derived cell therapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Vertex Pharmaceuticals ($780M deal)Umoja BiopharmaUniversity of Pittsburgh (research collaboration in immuno-oncology)
Beyond the preview
Go deeper on TreeFrog Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TreeFrog Therapeutics.